View More
This series of live workshops will cover the importance of LAG-3 as a new immunotherapy target and the emerging data on the mechanism of action, use, and safety of anti–LAG-3 immunotherapies across a range of malignancies. Accompanying these workshops will be a downloadable slideset, simulcasts, an expert commentary, a PDF practice resource, and an on-demand webcast.
Live webinars!
Webinar 1 - June 28, 2022
Webinar 2 - July 6, 2022
Webinar 3 - July 19, 2022
Download this PDF summary resource to learn more about LAG-3 as the latest validated immune checkpoint therapeutic target, the first approved LAG-3 therapy relatlimab, and investigational agents targeting LAG-3 across multiple tumor types.
Krista M. Rubin, MS, RN, FNP-BC
Released: March 23, 2022
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.